Daron Acemoglu (@DAcemogluMIT) on X
Short summary
Daron Acemoglu argues that while AI's potential for drug discovery is often used to justify massive investments, the evidence shows AI has delivered little so far—and redirecting some of that money toward proven public health interventions would do far more to improve American life expectancy.
- AI has produced minimal gains in actual drug discovery despite significant effort. A recent paper found that while AlphaFold predicted protein structures, there's "no evidence so far that more applied, early-stage drug development is targeting these proteins."
- The US has the lowest life expectancy among wealthy nations (about 5 years behind Switzerland, Sweden, Japan), mostly from preventable deaths before age 70 due to chronic disease, overdoses, and poor public health—not lack of new drugs.
- The US spends far more on healthcare than peer countries but too little on public health (preventive care, nutrition, immunization, primary care access), suggesting reallocating AI investment toward these proven interventions would yield better health outcomes.
Full summary
Daron Acemoglu challenges the argument that rapid AI investment is justified by promises of drug discovery and longer lifespans. The reality is messier. A recent paper by Hill and Stein found that while AlphaFold has generated significant downstream research on protein structures, there's no evidence yet that this is actually spurring early-stage drug development. Daphne Koller explains why: current AI excels at the final layer of drug development—creating new molecules for already well-understood diseases—but struggles with the harder problem of identifying entirely new disease mechanisms. That requires understanding disease biology where data is sparse, and it's still unclear whether today's AI models can handle that kind of work.
The uncomfortable part of Acemoglu's argument is that this doesn't matter much for American health anyway. The US has the lowest life expectancy among wealthy nations—about five years behind Switzerland, Sweden, Japan, and South Korea. Most of that gap comes from preventable deaths before age 70: chronic diseases, overdoses, and other causes rooted in public health failures. Americans skip vaccinations, eat poorly, lack access to primary care, and get bad health information. The country spends more on healthcare than peer economies but far less on public health, and what it does spend on public health is ineffective.
So here's the real question: if the goal is actually extending American lifespans, why pour massive resources into AI drug discovery when the money would do far more good fixing public health infrastructure? Other countries face the same drug discovery benefits but can also invest their own money in that. The bulk of global AI spending happens in the US anyway. Redirecting even some of those enormous investments toward preventable disease, immunization campaigns, and primary care access would likely deliver faster, bigger health gains than waiting for AI to crack new cures.